Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re: PTSC is a gamble and it sells at a price that is comparable to that gamble.

We probably are not only near our comparable value at the moment but quite likely we may see a PPS drift into the .30's.

On top of that, if we as longs estimate $50-75MM coming in the quarter, those in the investment community do also. The big worry is that we meet their expectation on cash influx, in total, and that alone will be only as expected with no real "juice' to power us forward.

We need ongoing revenues that are NOT one time payments, revenue that can be forecasted and built upon, so those who have the BIG $$$$ (Funds etc. etc.) are willing to put their capital into our company.

More information about ongoing M&A activity could help, at least info that can be discussed openly. The M&A is what we need more than anything right now IMO, and maybe even some PR's about the search for investment firms to help us in our search and completion of M&A is what we need now and until April.

If nothing regarding that is forthcoming these licenses we sign and announce, esp. with no "meat" behind the signings will have little or no effect on our PPS. April is not that far off, but even then IMO we and those who study the numbers for forecasting will not be able to discern who paid how much for what. If there are ongoing payments set up with the J's, that are not royalty based, that may help also if reported as they should be in the AP line of the results.

No matter what, with no M&A PR or activity I could easily see the April Q not affecting the PPS to a great degree...I hope I'm wrong, but that is my gut feeling right now.

JMHO.

Share
New Message
Please login to post a reply